Cisplatin-Induced Hearing Loss (CIHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cisplatin-induced hearing loss (CIHL) can arise due to various predisposing factors such as pre-existing conditions like hypoalbuminemia, anemia, renal failure, and noise-induced hearing loss, or from certain risk factors like the administration of loop diuretics, aminoglycoside antibiotics, radiotherapy affecting the inner ear, extremes of age (very young or elderly), as well as the duration and dosage regimen of cisplatin infusion, alongside genetic predispositions. Research indicates that between 11% and 97% of patients treated with cisplatin experience hearing loss, with an average occurrence rate of 62%. Cisplatin-induced tinnitus is also not uncommon. Ototoxicity can manifest within hours to days following cisplatin administration. Cisplatin primarily damages outer hair cells, progressing from the third to the first row, and to some extent affects inner hair cells of the organ of Corti in the basal turn of the cochlea, followed by alterations in sensorial cells located in the apex. Additionally, cisplatin targets supporting cells, marginal cells of the stria vascularis, and the spiral ligament, while also impacting the vestibular organs and spiral ganglion cells under experimental conditions. This resulting hearing loss can be highly debilitating for patients, especially those already grappling with impaired communication due to head and neck cancers, and often leads to depression and a diminished quality of life.
·
Around 50-60% of children treated with
cisplatin may experience CIHL, whereas 5-20% of those treated with carboplatin
may encounter some degree of irreversible hearing loss. This incidence rises to
80%-90% in individuals receiving cisplatin in combination with myeloablative
carboplatin.
Thelansis’s
“Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Cisplatin-Induced
Hearing Loss (CIHL) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cisplatin-Induced
Hearing Loss (CIHL) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cisplatin-Induced
Hearing Loss (CIHL) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Cisplatin-Induced
Hearing Loss (CIHL), Cisplatin-Induced Hearing Loss (CIHL) market outlook, Cisplatin-Induced Hearing Loss
(CIHL) competitive landscape, Cisplatin-Induced
Hearing Loss (CIHL) market forecast, Thelansis,
Primary market research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment